Nice | Empagliflozin in Type 2 Diabetes

5th June 2015 by Louise Hudman

Nice | Empagliflozin in Type 2 Diabetes

This is a new guideline from Nice. Empagliflozin is a selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor, which blocks glucose reabsorption in the kidneys and so causes increased urinary excretion. For other SGLT-2 inhibitors have been approved by NICE, see my post about Dapagliflozin.

Empagliflozin use in Type 2 Diabetes

  • as a 2nd drug in combination with metformin if they
    • can not take sulphonylureas.
    • are at significant risk of hypoglycaemia or its consequences.
  • as a 3rd drug with metformin and either a sulphonylurea or a thiazolinedione.
  • in combination with insulin with or without other drugs.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"We’ve worked with the NASGP now for over a decade, and have always been impressed with their commitment to promoting a really productive working relationship between practices and GP locums, with the ultimate aim of making sure patients receive the best care, no matter which GP they see."

Lynda Cox, Practice Cover

Lynda Cox, Practice Cover

See the full list of features within our NASGP membership plans

Membership